Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: A retrospective study

Oncology Reports

Volumn 32, Issue 6, 2014, Pages 2619-2627

  Liu, Mei ^a,b   Yang, Ya Jun ^a   Zheng, Hong ^a   Zhong, Xiao Rong ^a   Wang, Yu ^a   Wang, Zhu ^a   Wang, Yao Geng ^a   Wang, Yan Ping ^a  

^a SICHUAN UNIVERSITY   (China)

^b Chongqing Cancer Institute   (China)

Author keywords

4 hydroxy tamoxifen; Breast cancer; Complement dependent cytotoxicity; Membrane bound complement regulatory proteins; Trastuzumab

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEMBRANE COFACTOR PROTEIN; TRASTUZUMAB; COMPLEMENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; BREAST NEOPLASMS; COMPLEMENT SYSTEM PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84914679139     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3496     Document Type: Article

References (43)

1. Natsume A, Niwa R and Satoh M: Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther 3: 7-16, 2009.
2. Yamashita M, Katakura Y and Shirahata S: Recent advances in the generation of human monoclonal antibody. Cytotechnology 55: 55-60, 2007.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005.
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005.
5. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: study. Breast Cancer Res Treat 94: S5, 2005.
6. Nahta R and Esteva FJ: HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: e215, 2006.
7. Valabrega G, Montemurro F and Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18: 977-984, 2007.
8. Dalle S, Thieblemont C, Thomas L and Dumontet C: Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 8: 523-532, 2008.
9. Drebin JA, Link VC and Greene MI: Monoclonal antibodies specific for the neu oncogene product directly mediate antitumor effects in vivo. Oncogene 2: 387-394, 1988.
10. Mamidi S, Cinci M, Hasmann M, Fehring V and Kirschfink M: Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent antitumor activity of trastuzumab and pertuzumab. Mol Oncol 7: 580-594, 2013.
11. Prang N, Preithner S, Brischwein K, et al: Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 92: 342-349, 2005.
12. Yu J, Caragine T, Chen S, Morgan BP, Frey AB and Tomlinson S: Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin Exp Immunol 115: 13-18, 1999.
13. Mineo J F, Bordron A, Quintin-Roue I, et al: Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. Br J Cancer 91: 1195-1199, 2004.
14. Fishelson Z, Donin N, Zell S, Schultz S and Kirschfink M: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40: 109-123, 2003.
15. Gancz D and Fishelson Z: Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol 46: 2794-2800, 2009.
16. Macor P and Tedesco F: Complement as effector system in cancer immunotherapy. Immunol Lett 111: 6-13, 2007.
17. Hosch SB, Scheunemann P, Lüth M, et al: Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer. J Gastrointest Surg 5: 673-679, 2001.
18. Koretz K, Brüderlein S, Henne C and Möller P: Decayaccelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br J Cancer 66: 810-814, 1992.
19. Liu YC, Chen L, Peng SY and Hoang-Vu C: Role of CD97 (stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci 6: 913-918, 2005.
20. Loberg RD, Day LL, Dunn R, Kalikin LM and Pienta KJ: Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8: 69-78, 2006.
21. Zhao W P, Zhu B, Duan YZ and Chen ZT: Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep 21: 1405-1411, 2009.
22. Terui Y, Sakurai T, Mishima Y, et al: Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 97: 72-79, 2006.
23. Golay J, Lazzari M, Facchinetti V, et al: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98: 3383-3389, 2001.
24. Andoh A, Shimada M, Araki Y, Fujiyama Y and Bamba T: Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells. Cancer Immunol Immunother 50: 663-672, 2002.
25. Holla VR, Wang D, Brown JR, Mann JR, Katkuri S and DuBois RN: Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J Biol Chem 280: 476-483, 2005.
26. Xin YC, Gui SH and Ge SQ: Tamoxifen modulates the expression of complement inhibitory proteins on chorio-carcinoma cell line JAR. Shanghai J Immunol 1: 20-23, 2003.
27. Bjørge L and Matre R: Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Scand J Immunol 42: 512-516, 1995.
28. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
29. Ikeda J, Morii E, Liu Y, et al: Prognostic significance of CD55 expression in breast cancer. Clin Cancer Res 14: 4780-4786, 2008.
30. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J and Baselga J: Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749, 2001.
31. Subik K, Lee J F, Baxter L, et al: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer 4: 35-41, 2010.
32. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH and Saifuddin M: Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLv-I) and human cytomegalovirus (HCMv). J Immunol 155: 4376-4381, 1995.
33. Kolev M V, Tediose T, Sivasankar B, et al: Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. Pharmacogenomics J 10: 12-19, 2010.
34. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA and Armitage NC: Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52: 638-642, 2003.
35. Loberg RD, Wojno KJ, Day LL and Pienta KJ: Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology 66: 1321-1326, 2005.
36. Madjd Z, Durrant LG, Pinder SE, et al: Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)? Cancer Immunol Immunother 54: 149-156, 2005.
37. Macor P, Tripodo C, Zorzet S, et al: In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67: 10556-10563, 2007.
38. Bannerji R, Kitada S, Flinn I W, et al: Apoptotic regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 21: 1466-1471, 2003.
39. Bellone S, Roque D, Cocco E, et al: Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br J Cancer 106: 1543-1550, 2012.
40. Gelderman KA, Kuppen PJ, Okada N, Fleuren GJ and Gorter A: Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res 64: 4366-4372, 2004.
41. Argiris A, Wang CX, Whalen SG and DiGiovanna MP: Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10: 1409-1420, 2004.
42. Wang CX, Koay DC, Edwards A, et al: In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer. Breast Cancer Res Treat 92: 251-263, 2005.
43. Schild-Hay LJ, Leil TA, Divi RL, Olivero OA, Weston A and Poirier MC: Tamoxifen induces expression of immune response-related genes in cultured normal human mammary epithelial cells. Cancer Res 69: 1150-1155, 2009.